Sir Charles Locock and potassium bromide

Eadie, M. J.

doi:10.4997/jrcpe.2012.317

Cited by 26 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Historically, the first mention of bromide's application as an anti-epileptic agent was described in a Lancet paper in 1857, by Sir Charles Locock, Queen Victoria's obstetrician. The use of potassium bromide over the course of 14 months was reported to have successfully cured catamenial epilepsy in a group of 15 women, excluding 1 patient (10). The use of bromide subsequently saw widespread acceptance as an anti-epileptic agent up until the early 1900s, when more advanced drugs such as phenobarbitone superseded it.…”

Section: Anti-epileptic Agentmentioning

confidence: 99%

The role of endogenous bromotyrosine in health and disease

Sabir

Tan

Aris

et al. 2019

Free Radical Research

View full text Add to dashboard Cite

Bromotyrosine is a stable by-product of eosinophil peroxidase activity, a result of eosinophil activation during an inflammatory immune response. The elevated presence of bromotyrosine in tissue, blood and urine in medical conditions involving eosinophil activation has highlighted the potential role of bromotyrosine as a medical biomarker. This is highly beneficial in a paediatric setting as a urinary non-invasive biomarker. However, bromotyrosine and its derivatives may exert biological effects, such as protective effects in the brain and pathogenic effects in the thyroid. Understanding of these pathways may yield therapeutic advancements in medicine. In this review, we summarise the existing evidence present in literature relating to bromotyrosine formation and metabolism, identify the biological actions of bromotyrosine and evaluate the feasibility of bromotyrosine as a medical biomarker.

show abstract

Section: Anti-epileptic Agentmentioning

confidence: 99%

The role of endogenous bromotyrosine in health and disease

Sabir

Tan

Aris

et al. 2019

Free Radical Research

View full text Add to dashboard Cite

show abstract

“…In the mid‐1800s, it was recognized that various inorganic bromide salts resulted in sedative effects, and in the case of potassium bromide, caused impotence. Locock surmised that catamenial epilepsy (referred to at that time as “hysterical” epilepsy) might be amenable to potassium bromide treatment and found that this treatment effectively arrested epileptic seizures in 14 of 15 women . However, the larger adoption of bromides would not likely have been possible without independent evidence provided by Samuel Wilks (1824–1911), a prominent British physician, who was contemporaneous with Locock .…”

Section: Early History Of Epilepsy Treatmentmentioning

confidence: 99%

“…4 However, the larger adoption of bromides would not likely have been possible without independent evidence provided by Samuel Wilks (1824-1911), a prominent British physician, who was contemporaneous with Locock. 4 Nevertheless, potassium bromide represented the first drug therapy for epilepsy (and is still used largely in dogs with epilepsy and very rarely in humans). This medication, unfortunately, possesses a small therapeutic index, and can induce a variety of severe skin reactions and central nervous system effects, including lethargy, cachexia, delirium/psychosis, paresis, and even exacerbation of seizure activity.…”

mentioning

confidence: 99%

Brief history of anti‐seizure drug development

Rho

White

2018

Epilepsia Open

View full text Add to dashboard Cite

SummaryThe mainstay of therapy for epilepsy is anti‐seizure drugs (ASDs, also referred to as anticonvulsants and anti‐epileptic medications). Through much of the past century, only a handful for ASDs were available for clinical use. However, with the creation of the U.S. National Institutes of Health/National Institute of Neurological Disorders and Stroke (NINDS)–sponsored Anticonvulsant Screening Program (ASP), coupled with the emergence of high‐throughput screening platforms and methodologies, and advances in our understanding of the fundamental neurobiology of epilepsy, ASD development has greatly accelerated over the past 25 years. More than 18 new ASDs have been approved for clinical use since the inception of the ASP. Despite this remarkable success and the emergence of drugs possessing more favorable pharmacokinetic profiles that act on novel molecular targets, there has been increasing recognition that the paradigms for drug discovery have not yielded significant improvements in therapeutic efficacy, and that disease modification (i.e., anti‐epileptogenesis), among other challenges, must be addressed. Thus, with the renewed framework and mission of improving the lives of people with epilepsy, the name of the ASP was changed to the Epilepsy Therapy Screening Program (ETSP). This review briefly summarizes the history of ASD development and outlines some of the challenges and opportunities for the next generation of drug therapies for the epilepsy field.

show abstract

“…Amongst synthetic products, bromide , introduced in the 1860s, was used as a sedative and sleeping draught (L28, p. 192) [ 155 ]. Bromide overdose has toxic effects, but there is no mention of this in Grundriss .…”

Section: Treatments and Medical Technology Of The Daymentioning

confidence: 99%

An Outline of Psychiatry in Clinical Lectures

Miller¹,

Dennison²

2015

View full text Add to dashboard Cite

Sir Charles Locock and potassium bromide

Cited by 26 publications

References 27 publications

The role of endogenous bromotyrosine in health and disease

The role of endogenous bromotyrosine in health and disease

Brief history of anti‐seizure drug development

An Outline of Psychiatry in Clinical Lectures

Contact Info

Product

Resources

About